Ticker Symbol: AVTE
Aerovate Therapeutics Inc
$14.01 - 21-10-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001798749
Company Profile
aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: aerovatetx.com
CEO: N/A
Tags:
N/A
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $11.13
Change:
-$0.24
(
-2.11%)
Days Range: $11.03 - $11.93
Beta: 1.56
52wk. High: $30.79
52wk. Low: $10.51
Ytd. Change -64.12%
50 Day Moving Average: $12.99
200 Day Moving Average: $16.32
Shares Outstanding: 27650000
Valuation
Market Cap: 30.8B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A